Heme-regulated eIF2α kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency

被引:284
作者
Han, AP
Yu, C
Lu, LR
Fujiwara, Y
Browne, C
Chin, G
Fleming, M
Leboulch, P
Orkin, SH
Chen, JJ
机构
[1] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[2] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA
[6] Howard Hughes Med Inst, Boston, MA 02115 USA
关键词
apoptosis; erythropoiesis; heme-regulated eIF2 alpha kinase; iron deficiency; translation;
D O I
10.1093/emboj/20.23.6909
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although the physiological role of tissue-specific translational control of gene expression in mammals has long been suspected on the basis of biochemical studies, direct evidence has been lacking. Here, we report on the targeted disruption of the gene encoding the heme-regulated eIF2 alpha kinase (HRI) in mice. We establish that HRI, which is expressed predominantly in erythroid cells, regulates the synthesis of both alpha -and beta -globins in red blood cell (RBC) precursors by inhibiting the general translation initiation factor eIF2. This inhibition occurs when the intracellular concentration of heme declines, thereby preventing the synthesis of globin peptides in excess of heme. In iron-deficient HRI-/- mice, globins devoid of heme aggregated within the RBC and its precursors, resulting in a hyperchromic, normocytic anemia with decreased RBC counts, compensatory erythroid hyperplasia and accelerated apoptosis in bone marrow and spleen. Thus, HRI is a physiological regulator of gene expression and cell survival in the erythroid lineage.
引用
收藏
页码:6909 / 6918
页数:10
相关论文
共 52 条
  • [1] Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR
    Abraham, N
    Stojdl, DF
    Duncan, PI
    Méthot, N
    Ishii, T
    Dubé, M
    Vanderhyden, BC
    Atkins, HL
    Gray, DA
    McBurney, MW
    Koromilas, AE
    Brown, EG
    Sonenberg, N
    Bell, JC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (09) : 5953 - 5962
  • [2] Characterization of the hemin-sensitive eukaryotic initiation factor 2α kinase from mouse nonerythroid cells
    Berlanga, JJ
    Herrero, S
    de Haro, C
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (48) : 32340 - 32346
  • [3] Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2α kinase
    Berlanga, JJ
    Santoyo, J
    de Haro, C
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 265 (02): : 754 - 762
  • [4] BEUTLER E, 1983, HEMATOLOGY, P1603
  • [5] Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia
    Browne, PV
    Shalev, O
    Kuypers, FA
    Brugnara, C
    Solovey, A
    Mohandas, N
    Schrier, SL
    Hebbel, RP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) : 1459 - 1464
  • [6] Bull B.S., 2001, WILLIAMS HEMATOLOGY, P271
  • [7] CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788
  • [8] Heme-regulated eIF-2α kinase purifies as a hemoprotein
    Chefalo, PJ
    Oh, JH
    Rafie-Kolpin, M
    Kan, B
    Chen, JJ
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 258 (02): : 820 - 830
  • [9] CHEN JJ, 1989, J BIOL CHEM, V264, P9559
  • [10] Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529